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Abstract
Background: The cardiac troponins are biomarkers used for diagnosis of myocardial injury. They are also powerful
prognostic markers in many diseases and settings. Recently introduced high-sensitivity assays indicate that chronic
cardiac troponin elevations are common in response to cardiovascular (CV) morbidity. Type 2 diabetes mellitus
(T2DM) confers a high risk of CV disease, but little is known about chronic cardiac troponin elevations in diabetic
subjects. Accordingly, we aimed to understand the prevalence, determinants, and prognostic implications of
cardiac troponin T (cTnT) elevations measured with a high-sensitivity assay in patients with T2DM.
Methods: cTnT was measured in stored, frozen serum samples from 124 subjects enrolled in the Asker and Bærum
Cardiovascular Diabetes trial at baseline and at 2-year follow-up, if availabe (96 samples available). Results were
analyzed in relation to baseline variables, hospitalizations, and group assignment (multifactorial intensive versus
conventional diabetes care for lowering CV risk).
Results: One-hundred thirteen (90 %) had detectable cTnT at baseline and of those, 22 (18 % of the total
population) subjects had values above the 99th percentile for healthy controls (13.5 ng/L). Levels at baseline were
associated with conventional CV risk factors (age, renal function, gender). There was a strong correlation between
cTnT levels at the two time-points (r = 0.92, p > 0.001). Risk for hospitalizations during follow-up increased step-
wise by quartiles of hscTnT measured at baseline (p = 0.058).
Conclusions: Elevations of cTnT above the 99th percentile measured by a highly sensitive assay were encountered
frequently in a population of T2DM patients. cTnT levels appeared to be stable over time and associated with
conventional CV risk factors. Although a clear trend was present, no statistically robust associations with adverse
outcomes could be found.
Introduction
The majority of deaths in patients with type 2 diabetes
mellitus (T2DM) are due to cardiovascular (CV) disease.
Although hyperglycemia, the defining feature of T2DM,
is closely associated with microvascular and macrovas-
cular complications[1], studies have failed to demon-
strate that glucose lowering per se reduces the risk of
macrovascular events [2-4]. Thus, current understanding
suggests that broad, multiple intervention strategies
including lifestyle changes, aggressive blood pressure
and lipid lowering, in addition to glucose control, are
necessary for mitigating morbidity and mortality related
to macrovascular disease [5,6]. Consistent with this con-
cept, the prospective, randomized Asker and Bærum
Cardiovascular Diabetes (ABCD) trial on 120 T2DM
subjects found that structured care encompassing a
comprehensive and intensive preventive strategy reduced
the primary efficacy outcome of change in the estimated
10-year absolute risk for fatal coronary heart disease at
2 years compared to conventional care [7].
The cardiac troponins T and I are extremely sensitive
and specific biomarkers of myocardial necrosis and crucial
components of the diagnosis of myocardial infarction
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[8,9]. The recent emergence of several high-sensitivity
assays has shown that cardiac troponins can be chronically
elevated in response to CV comorbidities and that they
confer important prognostic information. The presence of
T2DM is a known predictor of elevated cardiac troponin
T in the general population with contemporary assays
[10], but the prevalence, determinants and prognostic
implications of cardiac troponin T elevations measured by
a high-sensitivity assay in T2DM subjects have not been
investigated. Furthermore, it is unknown whether troponin
levels are lowered by aggressive CV risk-factor modifica-
tion in this patient group. Accordingly, in the present post
hoc analysis of the ABCD study, we attempted to define
the distribution and determinants of cardiac troponin
T levels in patients enrolled in the trial at baseline, and
investigate whether the structured, intensive care delivered
in the ABCD trial results in lower cardiac troponin
T values after 2 years of follow-up. In addition, we wanted
to tentatively explore whether cardiac troponin T levels
were associated with hospitalizations during follow-up.
Methods
Setting, design and participants
We performed a post hoc analysis of the ABCD study
conducted at Vestre Viken, Asker and Baerum Hospital,
Rud, Norway from 2002 to 2006. The study enrolled
133 subjects with T2DM for a cross-sectional investiga-
tion of the prevalence of coronary artery disease. Exclu-
sion criteria were clinically significant peripheral
(defined as amputation-threatening ischemia) or cerebral
artery disease or type 1 DM (the presence of autoantibo-
dies towards pancreatic beta cells and insulin initiation
within one year since the diagnosis of T2DM). Partici-
pants underwent clinical examination, 24 hour Holter
monitoring and blood pressure measurements, stress
electrocardiogram, and testing of ventilatory oxygen
uptake, in addition to blood and urine sampling. 120 of
the original 133 participants had ≥ 1 CV risk factor
and agreed to be part of a prospective, randomized
controlled trial of intensive versus usual care in T2DM
subjects. Figure 1 provides an overview of the inclusion
and exclusion of patients. Individuals included in the
prospective trial were referred for voluntary stress echo-
cardiography and invasive coronary angiography. Details
of the design and results of the cross-sectional and
prospective studies have been published [7,11]. All parti-
cipants gave written informed consent and the studies
were conducted in accordance with the Helsinki
Declaration and approved by the Regional Ethics
Committee and the Norwegian Data Inspectorate.
Data collection and procedures
Cardiac troponin T was measured in blood samples at
baseline (n = 124) and 2-year follow-up (n = 96), if
available. Samples were stored at - 80°C for 4-8 years
and measured on the Roche Diagnostics (Basel, Switzer-
land) Cardiac troponin T assay by the electrochemilumi-
nescence method. The limit of the blank is 3 ng/L, the
limit of detection 5 ng/L, and the 99th percentile was
determined to be 13.5 ng/L in 616 apparently healthy
volunteers [12]. Assays were performed by personnel
unaware of the patient’s identity or other characteristics.
Details regarding sampling strategies and assay charac-
teristics for the laboratory determinations of the other
serum markers have been described previously [7,11].
Details of all procedures and clinical tests have been
published previously [7,11]. In brief, for the exercise test
we used a modified maximum symptom-limited 1-min
incremental exercise test on an electrically braked cycle
ergometer (Siemens-Elema, Germany). The patients
maintained a constant pedaling-rate of 60 rotations per
minute. Simultaneous haemodynamic monitoring was
performed and symptoms of chest pain were recorded
during exercise. A 12-lead Likar-Mason modified elec-
trocardiogram was continuously sampled every 2 ms
(500 Hz sampling rate) and converted to digital form
with a 12-bit resolution. Standard ST-segment depres-
sion criterion (> 1 mm [0.1 mV]) or additional horizon-
tal or down-sloping ST-segment depression at end
exercise was used for assessment of the ECG.
Dobutamine stress echocardiography was performed
using a staged protocol with dobutamine infusions up to
40 μg/kg/min in increments of 3 minutes with atropine
0,25-1,0 mg added when needed to obtain peak heart
rate [13]. Peak stress was defined as either of: new or
worsened left ventricular regional wall motion abnorm-
ality, HR > 220 - age (years), blood pressure > 200/110
mmHg, or patient discomfort. Ultrasound cine loops of
left ventricle imaged from 3 apical and 2 parasternal
imaging planes were obtained (Vivid 7 or Vivid 5 scan-
ners, GE Vingmed Sound, Horten, Norway) at rest, at
10 and 20 μg dobutamine/kg/min and at peak stress,
and transferred for off-line analysis. Left ventricular wall
motion analysis was performed by a blinded experienced
observer. Wall motion score index was assessed by use
of a 16 segments model of the left ventricle [14]. Rever-
sible myocardial ischemia was defined as new or pro-
gressing wall motion abnormality during test in > = 1
segment.
Coronary angiography was performed using standard
Judkins’ technique, with a percutaneous radial or femoral
approach using 6F diagnostic catheters (Cordis Corpora-
tion, Miami, FL, US) and the water-soluble, non-ionic,
dimeric contrast medium iodixanol (Visipaque 320 mg/
mL; Amersham Health, Oslo, Norway). The angiograms
were performed after routine referral to the catheteriza-
tion lab (194 ± 94 days after enrolment in the study) and
were independently analyzed semiquantitatively by two
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experienced cardiologists. Stenosis > 50% of lumen dia-
meter was defined as main vessel disease and patients
were categorized as 0-, 1-, 2- or 3-vessel disease. Stenosis
of the left main coronary artery of greater than 50% of
lumen diameter was considered to be 2-vessel disease.
Inter-observer variability of angiographic classifications
was 4.9 %. The operators were blinded to randomization
and hscTnT levels.
Hospitalizations were defined as hospital stays = > 24
hours and were adjudicated by the principal investigator
(OEJ) and study nurse at each follow-up visit and by
review of patient charts. Estimation of 10-year risk for
coronary artery disease was performed using the UK
Prospective Diabetes Study risk algorithm [15], a
diabetes-specific model that incorporates HbA1c, systo-
lic blood pressure total and HDL cholesterol, atrial
fibrillation, age, gender, ethnic group, smoking status
and duration of diabetes.
Statistical analysis
Continuous variables are presented as means with stan-
dard deviations or geometric means with 95th percen-
tiles as appropriate (median and interquartile range for
cardiac troponin T), and categorical variables as propor-
tions. Groups were defined by gender-specific quartiles
of cardiac troponin T at baseline or follow-up. Statistical
comparison of groups was performed by one-way
ANOVA (continouous variables) or chi-square tests
(categorical variables). Tests for trends were performed
by linear regression analysis for continuous variables
(assigning the median cardiac troponin T value for each
quartile category to each person in that category as the
independent variable in the model) and Cochran-Armi-
tage trend test for categorical variables. For comparison
of cardiac troponin T values between groups (i.e. men
vs. women, intensive vs. conventional care, and baseline
vs. 2-year samples), Wilcoxon signed-rank or Wilcoxon
rank-sum tests were employed as appropriate. Reported
correlation coefficients are Spearman rank correlations.
Event rates (i.e. hospitalizations) are presented as
proportions. A p-value of less than 0.05 (two sided) was
considered to indicate statistical significance. All statisti-
cal analyses were performed on SPSS (version 16.0,
SPSS Inc., Chicago, Ill, US)
Results
Distribution of troponin T values and patient
characteristics
At baseline, median (interquartile range) troponin T for
all samples were 7.3 (6.1) ng/L. For patients in whom
two measurements were available, median (interquartile
range) troponin T values were 7.5 (7.7) ng/L and
Figure 1 Flow chart showing number of patients included for cross-sectional and prospective investigation and reasons for exclusion;
and the number of patients who had troponin T measured at the two time points.
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5.8 (11.8) ng/L at baseline and follow-up, respectively (p
< 0.001 for change). Hundred -and-eleven patients
(90%) had measureable levels of troponin T at baseline
and of those, 22 patients had values above the 99th per-
centile of a reference population. Troponin T levels
were higher in men than in women (median, 8.2 ng/L
vs. 5.6 ng/L; p < 0.01). The distribution of troponin
T concentrations at baseline is shown in figure 2.
Patient characteristics according to gender-specific quar-
tiles of baseline troponin T levels are shown in table 1.
Troponin T levels were associated with several conven-
tional risk factors (increasing age, male gender, renal
impairment and duration of diabetes). There was a
strong correlation between troponin T values at baseline
and follow-up (rho = 0.92; p < 0.001) (figure 3).
Troponin T values according to CV risk, hospitalizations
and treatment strategy
The number of patients with all-cause and diabetes/
CV-related hospitalizations increased in a step-wise
fashion by quartiles of troponin T values at baseline
(figure 4). Patients without hospitalizations experienced
a statistically significant larger drop in median (inter-
quartiles range) troponin T values during follow-up
compared to patients hospitalized for any reason
(- 2.0 ng/L [3.7] versus - 1.2 [4.7] ng/L, p = 0.019) and/
or for diabetes-related reasons (- 1.8 [3.5] ng/L versus -
1.1 [6.4] ng/L, p = 0.032).
No differences were seen in troponin T levels at base-
line (7.2 ng/L [8.0] versus 7.7 ng/L [8.0] for the intensive
and conventional strategy, respectively), at 2 years
(5.7 ng/L [12.7] versus 5.9 ng/L [11.7]), or in the change
in values between the structured and conventional
treatment groups.
Discussion
In a relatively young and healthy T2DM population we
found that circulating troponin T were measureable in
90 % of individuals by the new high-sensitivity assay,
and that a substantial proportion had levels above the
99th percentile of a reference population. Troponin
T values were associated with several conventional risk
factors for CV disease, and concentrations of troponin
T remained largely stable throughout the follow-up per-
iod. These observations imply that in this patient popu-
lation, troponin T release reflects underlying and
chronic pathophysiological processes. Thus, troponin
T may be a useful surrogate marker to define risk
among subjects with T2DM, and may facilitate early
identification of patients with subclinical CV disease and
other high-risk individuals.
Using the older and less sensitive conventional assay, a
previous analysis observed elevated troponin T values in
about 0.7 % of the general population [10]. Elevations
were associated with established CV disease or high-risk
phenotypes including T2DM. This is consistent with the
substantial proportion of T2DM patient with troponin
T elevations above the 99th percentile found in the
present dataset. Our results also support and extend pre-
vious investigations of troponin T values in populations
with established CV disease [16-18]. In these conditions,
mechanisms of troponin release is thought to include
mismatch between oxygen supply and demand, inflam-
mation, apoptosis, and myocardial strain [19,20]. We
Figure 2 Distribution of cardiac troponin T by the high-sensitivity assay in patients with type 2 diabetes mellitus.
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found a consistent trend of higher proportions of patients
with coronary artery disease indicated by coronary angio-
graphy, or positive exercise and stress-echocardiography
tests, in quartiles of increasing troponin T values. How-
ever, none of these differences amounted to statistical
significance which could indicate that our study was
underpowered to establish these relationships in a statis-
tically robust fashion. The finding of a negative correla-
tion between ventilatory oxygen uptake and troponin T
values fits with the well-established association between
CV disease and aerobic capacity [21,22], and may reflect
the cardioprotective properties of physical exercise.
We were not able to demonstrate that intensive, struc-
tured care translated into lower troponin T values,
despite the fact that such interventions improved risk
profiles (lipds, blood pressure, hyperglycemia) as
described in the primary report from the ABCD trial [7].
Possibly, a longer follow-up of patients is needed to
detect such differences in troponin T levels. Overall,
there was a small, albeit highly statistically significant
reduction in troponin T levels during the follow-up. This
trend may reflect an analytical basis, or, alternatively, the
efficacy of therapeutic interventions in the population as
a whole (as opposed to the structured care group alone).
Table 1 Comparison of variables between subjects stratified by cardiac troponin T levels
Distribution (n = 124) Quartile 1
(n = 31)
Quartile 2
(n = 31)
Quartile 3
(n = 31)
Quartile 4
(n = 31)
P-value* P-value for trend†
Cardiac troponin T (ng/L), range
Men 0.00 - 5.73 5.74 - 8.19 8.20 - 12.62 12.62 - 41.69
Women 0.00 - 3.00 3.01 - 5.64 5.65 - 8.48 8.49 - 30.42
Demographic and clinical data
Age (years, mean, SD) 52 (10) 58 (8) 62 (9) 62 (9) < 0.001 < 0.001
BMI (kg/h2, mean, SD) 30 (7) 30 (4) 31 (5) 29 (6) 0.586 0.612
24 h systolic BP (mm/Hg, mean, SD) 127 (14) 133 (10) 136 (12) 133 (18) 0.079 0.124
24 h diastolic BP (mm/Hg, mean, SD) 76 (9) 79 (7) 80 (7) 76 (9) 0.231 0.839
S-L voltage criteria (mm, mean, SD) 21 (8) 22 (8) 20 (7) 21 (9) 0.575 0.908
Ejection fraction (%, mean, SD) 63 (10) 63 (8) 63 (5) 64 (8) 0.907 0.546
V02 max (liters/minute, mean, SD) 2.3 (0.6) 2.1 (0.6) 2.1 (0.7) 1.9 (0.7) 0.188 0.036
Medical history
Duration of diabetes (years, mean, SD) 5 (5) 7 (6) 5 (6) 10 (8) 0.008 0.005
Coronary artery disease 3 (10%) 5 (16%) 4 (13%) 3 (10%) 0.841 0.902
Hypertension 18 (58%) 21 (68%) 21 (68%) 24 (77%) 0.448 0.124
Current smoker 4 (13%) 4 (13%) 3 (10%) 3 (10%) 0.956 0.612
Laboratory determinations
BNP (pmol/L, geometric mean, 95th percentile) 12 (8-18) 8 (6-12) 12 (8-17) 16 (9-27) 0.211 0.163
Cholesterol (mmol/L, mean, SD) 4.9 (1) 4.9 (1) 5.2 (1) 4.8 (1) 0.492 0.740
CRP (g/dL, geometric mean, 95th percentile) 3 (2-4) 2 (2-3) 3 (2-4) 2 (2-3) 0.530 0.554
Hb1Ac (%, mean, SD) 7.4 (1) 7.4 (2) 7.4 (2) 7.8 (2) 0.641 0.254
eGFR (Cockroft-Gault) (ml/min, mean, SD) 137 (55) 120 (37) 115 (37) 102 (33) 0.011 0.001
Microalbuminuria (ug/min, geometric mean, 95th percentile) 15 (11-22) 14 (11-19) 22 (15-30) 18 (13-25) 0.285 0.306
Exercise ECG (n = 124)
Number of patients 31 31 31 31
Ischemia 9 (29%) 8 (26 %) 10 (32%) 13 (42%) 0.559 0.231
Angiography (n = 85)
Number of patients 19 20 21 25
Coronary disease 2 (9%) 6 (30%) 5 (24%) 9 (36%) 0.273 0.098
Stress echocardiography (n = 87)
Number of patients 20 22 22 23
Reversible ischemia 3 (15%) 6 (27%) 6 (27%) 7 (30%) 0.674 0.283
* P-value is for comparison between groups and derived from one-way ANOVA (contionuous variables) or Chi-Square test (categorical variables).
† For continuous variables, the test for trend is based on assigning the median troponin T value for each quartile category to each person in that category and
then treating these four values as a continuous, independent variable in a linear regression model. For categorical variables, the test is based on the Cochran-
Armitage trend test.
SD = standard deviation; BMI = body-mass index; BP = blood pressure; S-L = Sokolow-Lyon; BNP, = Brain-natriuretic peptide; CRP = C-reactive protein; eGFR =
estimated glomerular filtration rate.
Hallén et al. Cardiovascular Diabetology 2010, 9:52
http://www.cardiab.com/content/9/1/52
Page 5 of 8
Figure 3 Scatter plot of cardiac troponin T values at baseline and 2 years.
Figure 4 Bar charts of all-cause and diabetes-related hospitalizations according to cardiac troponin T levels stratified by quartiles at
baseline. P-value for trend is 0.058 (all-cause) and .055 (diabetes-related). CV = cardiovascular
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The follow-up at 2 years allowed us to tentatively
probe the prognostic properties of troponin T, although
the post hoc design restricts interpretation and some
important limitations should be recognized: First,
according to the study protocol, hospitalizations were
only classified as all-cause or diabetes/CV-related. It
would have been instructive to also consider only CV
hospitalizations. Second, adjustments for relevant covari-
ates were not possible due to the low number of
patients and endpoints. In light of these limitations no
inferences can be drawn on the basis of the trend of
increasing hospitalizations across quartiles of increasing
troponin T values, even though the prognostic value of
troponin T that these numbers allude to are in agree-
ment with previous reports from other much larger
populations [16,17]. Interestingly, patients with no hos-
pitalizations experienced a statistically significant larger
drop in troponin T values compared to patients who
were hospitalized. This is an intriguing corollary to the
general trend of very stable elevations in the long term
and could be taken to suggest that even small alterations
in troponin T levels are indicative of changes in the
underlying cardiac status of patients [18].
The larger context of the present study is the increas-
ing use of circulating biomarkers for diagnostic and
prognostic purposes - as well as to directly inform treat-
ment decisions - in many fields in medicine. Cardiovas-
cular diseases and associated conditions like diabetes are
no exceptions, as new studies are emerging defining
novel biomarkers as well as exploring the role of well-
known markers in new contexts [23,24]. In response to
these developments benchmarks have been proposed for
evaluation of the clinical usefulness of biomarkers [25].
The cardiac troponins are well-established biomarkers
recognized as providing diagnostic and prognostic infor-
mation in both acute and chronic conditions. Recent
studies have shown that the novel high-sensitivity tropo-
nin assays further improve diagnostic and prognostic
performance compared to the conventional assays
[16,17,26]. Our study extends these findings to a dia-
betic population and suggests some clinical implications.
They alert the clinical community that individuals with
T2DM - even if fairly young and without much apparent
comorbidity - have a substantial probability of having a
chronically elevated troponin T value with the new high
sensitivity assay. In terms of diagnostic testing, these
observations underline the importance of the rising and/
or falling pattern, as suggested by the guidelines, to
identify those who are having acute myocardial infarc-
tions in this population [8,27]. For prognostic purposes,
the relationship we observed of troponin T with future
hospitalizations and several other risk factors could
point to a future role of the biomarker as a risk stratifi-
cation tool in this context, but the data presented here
should be considered preliminary and need to be vali-
dated in a larger cohort where adjustment can be made
for other established risk factors.
Some important limitations with this investigation
have already been mentioned and others should also be
considered. This was a post hoc study performed in a
relatively small cohort and due to the low absolute
number of patients and events, we were not able to
explore our data in multivariable regression models.
Clearly, this represents a major weakness of our study.
Yet, our findings fit well with the current understanding
of the distribution and prognostic properties of tropo-
nins in populations with established, or at high risk for,
CV disease (14, 15, 16). It is likely that some of the
troponin T elevations seen in our population compared
to the reference population are related to increased age,
although increases with this assay were not reported as
part of the assay validation. In any case, this does not
restrict interpretation of the results, as our population is
representative of a real-life T2DM population; and that
regardless of cause troponin-release confers a higher
risk of CV events and death. Measurements of baseline
and 2-year troponin T samples were performed at differ-
ent time-points, which increase the analytical variability
and may explain the slight fall in troponin T levels dur-
ing follow-up.
In conclusion, in a population of T2DM patients, we
found that almost 1 in 5 had troponin T values above
the 99th percentile of a reference population when mea-
sured by a highly sensitive assay. Levels of troponin
T were stable over time, associated with conventional
risk factors, and displayed a graded relationship with
hospitalizations although this trend was not statistically
significant.
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